Schulte Roth & Zabel advised Farallon Capital Management on the deal. Farallon announced the successful proxy contest at Exelixis, Inc., a company innovating next-generation medicines and regimens...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here